MedTrace Logo

Mechanical Thrombectomy With the FlowTriever Device in Acute Pulmonary Embolism - a Retrospective Analysis

NCT06187987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2025-05-20

No results posted yet for this study

Summary

International guidelines recommend intravenous thrombolysis (IVT) for high-risk pulmonary embolism (PE). In high-risk PE where IVT is contraindicated or has failed, surgical embolectomy or catheter-directed intervention (CDI) is recommended. CDI is also recommended as an alternative in patients with intermediate-risk PE with haemodynamic deterioration during anticoagulation treatment.

Although there is a lack of randomized studies comparing CDI to anticoagulation or systemic thrombolysis in PE, several studies and recent meta-analyses have shown that CDI is an effective treatment that is associated with fewer complications than IVT, especially bleeding.

Conditions

Interventions

DEVICE

Mechanical thrombectomy

Aspirational mechanical thrombectomy

DRUG

Intravenous thrombolysis

Intravenous thrombolysis with tissue-type plasminogen activator (tPA)

Sponsors & Collaborators

  • Stockholm South General Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Danderyd Hospital

    collaborator OTHER

  • University Hospital, Linkoeping

    collaborator OTHER

  • Sunderby Hospital

    collaborator OTHER

  • Kristina Svennerholm

    lead OTHER

Principal Investigators

  • Kristina Svennerholm, MD, PhD · Sahlgrenska University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2025-01-31
Completion
2025-03-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06187987 on ClinicalTrials.gov